Becton Dickinson 

R$267.3
491
+R$8.86+3.43% Monday 18:59

統計

當日最高
268.92
當日最低
263.25
52週最高
272.01
52週最低
214.7
成交量
301
平均成交量
47
市值
384.15B
市盈率
48.7
股息收益率
1.11%
股息
2.97

即將到來

股息

1.11%股息收益率
10年增長
N/A
5年增長率
N/A
3年增長率
-7.44%
1年增長率
-6.12%

收益

7Nov確認
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
下一個
2.4
2.86
3.33
3.79
預期每股收益
3.794103
實際每股收益
N/A

人們還關注

此列表基於在 Stock Events 上關注 B1DX34.SA 的人的關注列表。這不是投資建議。

競爭者

這個列表是基於最近市場事件的分析。這不是投資建議。

關於

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company's BD Medical segment provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication and infusion therapy delivery systems, medication compounding workflow systems, automated medication dispensing and supply management systems, and medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes; and prefillable drug delivery systems. Its BD Life Sciences segment offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, microorganism identification and drug susceptibility, and liquid-based cytology systems, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent systems, and solutions for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. The company's BD Interventional segment provides hernia and soft tissue repair, biological and bioresorbable grafts, biosurgery, and other surgical products; surgical infection prevention, surgical and laparoscopic instrumentation products; peripheral intervention products; and urology and critical care products. The company was founded in 1897 and is based in Franklin Lakes, New Jersey.
Show more...
首席執行官
Mr. Thomas E. Polen Jr.
員工
77000
國家
United States
ISIN
BRB1DXBDR008

上市公司